Welcome
Support Centre
23 July 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Controlled Antenatal Thyroid Screening study
ISRCTN ISRCTN46178175
DOI 10.1186/ISRCTN46178175
ClinicalTrials.gov identifier
EudraCT number
Public title Controlled Antenatal Thyroid Screening study
Scientific title Randomised controlled trial of the effect of gestational thyroid hormone intervention therapy on childhood development
Acronym CATS
Serial number at source 065143
Study hypothesis Aim is to evaluate strategy of screening of thyroid function in early pregnancy.
Lay summary Background and study aims.
There is evidence from previous studies that low thyroid function during pregnancy may affect the intelligence quotient (IQ) of the child. However there have been no prospective studies to confirm this. We carried out a study to answer the question: Does testing thyroid function in early pregnancy and treating those women with underactive thyroids improve the IQ of their children?

Who can participate?
We recruited 22000 women pregnant with one baby (singleton pregnancies) before 16 weeks gestation who were not taking thyroid medication.

What does the study involve?
Blood samples were randomly allocated to a screen group and a control group. Thyroid testing was done immediately in all samples from the screen group. The control group samples were stored until the woman delivered the baby and the thyroid test was then carried out. Note: at the time of this trial (2002) there was no routine screening of thyroid function in pregnant women. The screen group women who were found to have an underactive thyroid received Levothyroxine daily for the length of the pregnancy. The control group received no treatment during pregnancy. The women who had an underactive thyroid diagnosed after delivery were referred to their general practitioner for standard care.

What are the possible benefits and risks of participating?
The women participating had a 50% chance of having thyroid function measured during early pregnancy (compared to 0% chance in normal practice). They then had the opportunity to see if the thyroxine intervention improved the IQ of their child compared to the children born to mothers from the control group. Side effects of thyroxine include palpitations and tiredness. Thyroid testing was done in women taking thyroxine 6 weeks after starting and again at 30 weeks of pregnancy. Less than 5% of women required a dose adjustment.

Where is the study run from?
The study was run from the University Hospital of Wales, Cardiff University. There were approximately 8 centres including one in Turin, Italy.

When is the study starting and how long is it expected to run for?
The study started in 2002 and ended in 2010.

Who is funding the study?
Wellcome Trust

Who is the main contact?
Professor JH Lazarus
Lazarus@cf.ac.uk
Ethics approval Trent Multi-Centre Research Ethics Committee gave approval on the 24th June 2004 (ref: MREC/04/4/026)
Study design Multicentre, randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Childhood Development
Participants - inclusion criteria All pregnant women (aged 18 - 45 years) before 16 weeks gestation
Participants - exclusion criteria 1. Twin pregnancy
2. Thyroid treatment (T4 or antithyroid drugs)
Anticipated start date 01/06/2002
Anticipated end date 01/06/2010
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 22,000 - recruitment closed on 31st May 2006
Interventions Please note that, as of 18 January 2007, this trial is closed to recruitment: follow up continuing

Sera obtained from pregnant women before 16 weeks gestation. Sera randomised to 'screen' (T4 and Thyroid Stimulating Hormones [TSH] measured at time of randomisation) and 'control' (hormones measured post delivery) groups. Thyroxine intervention given to screen group with low T4/high TSH and to control group postpartum.
This is the only prospective randomised intervention trial of thyroxine in early pregnancy.
Primary outcome measure(s) Intelligence Quotient (IQ) of children in screen and control groups.
Secondary outcome measure(s) No secondary outcome measures
Sources of funding The Wellcome Trust (UK) (grant ref: GRO65143MA)
Trial website
Publications 1. 2012 results in http://www.ncbi.nlm.nih.gov/pubmed/22316443
Contact name Prof  John H  Lazarus
  Address Cardiff University
University Hospital of Wales
Professor of Clinical Endocrinology/
Heath Park
  City/town Cardiff
  Zip/Postcode CF14 4XN
  Country United Kingdom
  Tel +44 (0)29 20 742193
  Fax +44 (0)29 20 742193
  Email Lazarus@cf.ac.uk
Sponsor Cardiff University (UK)
  Address McKenzie House
Physical and Financial Resources
30-36 Newport Road
PO Box 497
  City/town Cardiff
  Zip/Postcode CF10 3XR
  Country United Kingdom
  Tel +44 (0)29 2087 9255
  Email Arnoldc1@cardiff.ac.uk
  Sponsor website: http://www.cardiff.ac.uk/index.html
Date applied 22/07/2005
Last edited 08/01/2013
Date ISRCTN assigned 22/07/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.